Marksans Pharma Ltd Financials
Company Logo

Marksans Pharma Ltd Financial Statement

Marksans Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue262.68
Operating Expense213.26
Net Profit32.02
Net Profit Margin12.19
Earning Per Share0.71
EBIDTA49.50
Effective Tax Rate20.96

Marksans Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Total Revenue Annual655.20
Operating Expenses Annual563.30
Operating Profit Annual152.39
Interest Annual3.61
Depreciation16.15
Net Profit Annual102.87
Tax Annual29.17

Marksans Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning148.31
Cash Flow from Operations34.05
Cash Flow from Investing-114.22
Cash Flow from Financing-26.22
Cash Flow at the End41.93

Marksans Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)23.67
PBIT Margin (%)20.26
PBT Margin (%)-0.21
Net PROFIT Margin (%)15.68
Return On Networth / Equity (%)11.46
Return On Networth /Employed (%)14.67
Return On Assets (%)11.29
Total Debt / Equity (X)0.01
Asset Turnover Ratio (%)0.72

Marksans Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual271.58
Total Current Assets Annual947.70
Non Current Assets Annual568.33
Total Shareholders Funds Annual1,222.71
Total Assets Annual1,516.04

Marksans Pharma Ltd Earning Calls

EPS (INR)

Expected

1.96

Reported

1.96

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Sep 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Marksans Pharma Ltd has a market capitalization of 6,867.70 Cr. Value Research classifies it as a Mid-Cap company.
Yes, Marksans Pharma Ltd is debt-free with a debt-to-equity ratio of 0.01.
In FY 2023 , Marksans Pharma Ltd recorded a total revenue of approximately 853.27 Cr marking a significant milestone in the company's financial performance.
Marksans Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.7% and 0.1% annually, respectively..
Marksans Pharma Ltd's current PE ratio is 51.34.
Marksans Pharma Ltd's ROCE averaged 14.5% from the FY ending March 2022 to 2024, with a median of 14.0%. It peaked at 17.3% in March 2022, reflecting strong capital efficiency over the period..
Marksans Pharma Ltd's latest EBIT is Rs. 172.88 Cr, surpassing the average EBIT of Rs. 148.95 Cr over the 5 years..